Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin-dependent diabetes mellitus.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  1993-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 8324945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.

  1992cited by this paper
• Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein.

  1987cited by this paper

• Therapeutic Enhancement of Protective Immunity during Experimental Leishmaniasis

  2011cites this paper
• Immunopharmacology Reviews Volume 2

  2011cites this paper
• Targeting of IL-2 receptor with a caspase fusion protein disrupts autoimmunity in prediabetic and diabetic NOD mice

  2010cites this paper
• Suppression of murine experimental autoimmune encephalomyelitis by interleukin-2 receptor targeted fusion toxin, DAB(389)IL-2.

  2010cites this paper
• Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients.

  2010cites this paper
• A Fusion Protein Composed of IL‐2 and Caspase‐3 Ameliorates the Outcome of Experimental Inflammatory Colitis

  2009cites this paper
• Targeted therapy to the IL‐2R using diphtheria toxin and caspase‐3 fusion proteins modulates Treg and ameliorates inflammatory colitis

  2009cites this paper
• Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.

  2008cites this paper
• Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.

  2007cites this paper
• Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.

  2007cites this paper
• Clinical trials in rheumatic diseases: designs and limitations.

  2004cites this paper
• Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.

  2003cites this paper
• Targeted toxins

  1999cites this paper
• Management of therapy-resistant rheumatoid arthritis.

  1999cites this paper
• Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells.

  1998cites this paper
• Immunotoxins: an update.

  1996cites this paper
• Biologic Interventions in Autoimmune Diseases

  1996cites this paper
• Anti-human immunodeficiency virus immunoconjugates.

  1995cites this paper
• 4 – Therapy for Rheumatoid Arthritis

  1995cites this paper
• Are there special considerations relevant to trials of biologic agents?

  1994cites this paper
• Immunotoxins against cancer.

  1994cites this paper
• Monoclonal antibody therapy in rheumatic disease.

  1994cites this paper